Free Trial
NASDAQ:PMN

Promis Neurosciences Q1 2026 Earnings Report

Promis Neurosciences logo
$10.59 -0.09 (-0.87%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Promis Neurosciences EPS Results

Actual EPS
-$1.26
Consensus EPS
-$1.06
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Promis Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Promis Neurosciences Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Promis Neurosciences Earnings Headlines

Analysts Set Promis Neurosciences (NASDAQ:PMN) PT at $42.67
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Promis Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email.

About Promis Neurosciences

Promis Neurosciences (NASDAQ:PMN), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration.

Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies.

The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.

View Promis Neurosciences Profile